Paul Hughes

Oct 10, 2024 | jdsupra.com | Paul S. Gadiock |Paul Hughes |Marshall Jackson

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved” for all presentations of the drug. An end to the shortage has important implications for industry stakeholders at various points in the medication’s supply chain. Compounding pharmacies and providers should be aware of the impact this change in shortage status has on their operations.

Oct 9, 2024 | lexology.com | James Ravitz |Paul S. Gadiock |Marshall Jackson |Lisa S. Mazur |Patrick Zanayed |Paul Hughes | +1 more

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved” for all presentations of the drug. An end to the shortage has important implications for industry stakeholders at various points in the medication’s supply chain. Compounding pharmacies and providers should be aware of the impact this change in shortage status has on their operations.

Jul 31, 2024 | jdsupra.com | Emily Cook |Paul Hughes |Tony Maida

At the end of the 2024 term, the executive branch struck out when the US Supreme Court issued three separate decisions along ideological lines that have the potential to materially weaken the enforcement authority of federal administrative agencies. First, the Court overruled the long-standing Chevron doctrine that instructed courts to defer to an agency’s permissible interpretation of ambiguous statutes.

Jul 31, 2024 | lexology.com | Emily Cook |Paul Hughes |Tony Maida |Drew Elizabeth McCormick |Laura M. McLane

At the end of the 2024 term, the executive branch struck out when the US Supreme Court issued three separate decisions along ideological lines that have the potential to materially weaken the enforcement authority of federal administrative agencies. First, the Court overruled the long-standing Chevron doctrine that instructed courts to defer to an agency’s permissible interpretation of ambiguous statutes.

Jul 9, 2024 | mwe.com | Emily Cook |Paul Hughes

As the healthcare regulatory landscape rapidly evolves, especially in the wake of the US Supreme Court’s Loper Bright decision, hospitals and health systems must keep up with emerging litigation trends and policy developments. Join us for a webinar exploring substantial new opportunities for health systems to advance policy and fiscal goals via regulatory litigation. We will examine these trends, their broad applicability and the far-reaching implications they present.